PHARMACOKINETICS OF AGALSIDASE ALPHA AND BETA IN THREE PATIENTS WITH FABRY DISEASE

被引：0
|
作者：
Okada, S. [1 ]
Tanaka, A. [1 ]
Takeda, T. [1 ]
Kobayashi, I. [1 ]
Ishimura, E. [1 ]
Negoro, N. [1 ]
Nishizawa, Y. [1 ]
Yamano, T. [1 ]
Yoshiyama, N. [1 ]
机构：
[1] Osaka City Univ, Grad Sch Med, Osaka 558, Japan
来源：
MOLECULAR GENETICS AND METABOLISM | 2009年 / 98卷 / 1-2期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
475
引用
收藏
页码：88 / 88
页数：1
相关论文
共 50 条
  • [1] Disease progress in patients with Morbus Fabry after switching from agalsidase beta to agalsidase alpha
    Reidt, S.
    Namdar, M.
    Serra, A.
    Krayenbuehl, P. A.
    Gruner, C.
    Keller, D. I.
    Luescher, T. F.
    Schmied, C.
    [J]. INTERNAL MEDICINE JOURNAL, 2014, 44 (02) : 205 - 207
  • [2] AGALSIDASE ALFA AND AGALSIDASE BETA FOR TREATMENT OF FABRY DISEASE
    Costa, M. G.
    Santos, M.
    Senna, K.
    [J]. VALUE IN HEALTH, 2018, 21 : S439 - S440
  • [3] Agalsidase beta (Fabrazyme) for Fabry disease
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2003, 45 (1165): : 74 - 75
  • [4] Spotlight on agalsidase beta in Fabry disease
    Keating, Gillian M.
    Simpson, Dene
    [J]. BIODRUGS, 2007, 21 (04) : 269 - 271
  • [5] SAFETY AND TOLERABILITY OF AGALSIDASE ALFA IN PATIENTS WITH FABRY DISEASE FORMERLY TREATED WITH AGALSIDASE BETA
    Fernhoff, P.
    Goker-Alpan, O.
    Holida, M.
    Nedd, K.
    Barshop, B. A.
    Mardach, R.
    Ibrahim, J.
    Lien, Y. H.
    Rever, B.
    Hillman, R.
    Weinreb, N.
    Boyd, E.
    Desai, A.
    Forte, R.
    Crombez, E.
    Martin, R.
    Amato, D.
    [J]. JOURNAL OF INHERITED METABOLIC DISEASE, 2011, 34 : S227 - S227
  • [6] Effect of changing therapy from agalsidase beta to agalsidase alfa in patients with Fabry disease
    West, M
    Lemoine, K
    [J]. ACTA PAEDIATRICA, 2006, 95 : 136 - 136
  • [7] Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta
    Linthorst, GE
    Hollak, CEM
    Donker-Koopman, WE
    Strijland, A
    Aerts, JMFG
    [J]. KIDNEY INTERNATIONAL, 2004, 66 (04) : 1589 - 1595
  • [8] A COST ANALYSIS ON COMPLICATIONS OF FABRY DISEASE PATIENTS TREATED WITH AGALSIDASE ALFA AND AGALSIDASE BETA IN COLOMBIA
    Londono, S.
    Ossa, M. E.
    Becerra, J.
    Solano, D. A.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S91 - S91
  • [9] Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha
    Tanaka, Akemi
    Takeda, Taisuke
    Hoshina, Takao
    Fukai, Kazuyoshi
    Yamano, Tsunekazu
    [J]. JOURNAL OF INHERITED METABOLIC DISEASE, 2010, 33 : S249 - S252
  • [10] Safety reduction of agalsidase beta infusion time in Fabry disease patients
    de Juan-Ribera, Joaquin
    Gonzalez Llopis, Francisco Angel
    Bosque Munoz, Eduardo
    [J]. MOLECULAR GENETICS AND METABOLISM, 2022, 135 (02) : S35 - S36
12345